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Background. IgG4-related disease (IgG4-RD) is a ﬁbroinﬂammatory condition. T-cells play a crucial role in the pathogenesis, and
therefore, serum soluble interleukin-2 receptor (sIL-2R) may be a potential biomarker.Method. We studied the levels of sIL-2R in
26 histologically proven IgG4-RD patients with available serum sIL-2R and compared them to those in newly diagnosed and
untreated sarcoidosis patients (n = 78) and controls (n = 101) and the serum sIL-2R levels in patients after treatment of IgG4-
RD (n = 15). The disease activity was measured using the IgG4-Related Disease Responder Index (IgG4-RD RI). Results. Median
serum sIL-2R in IgG4-RD patients was 4667 pg/ml compared to 1515 pg/ml in controls (P < 0 001) and 6050 pg/ml in
sarcoidosis patients (P = 0 004 compared to IgG4-RD). All IgG4-RD patients had elevated serum sIL-2R levels compared to the
reference value of <2500 pg/ml in controls and 85% elevated serum IgG4; however, these did not correlate with each other. Both
serum sIL-2R and IgG4 levels declined signiﬁcantly after treatment (P = 0 001 and P = 0 01, resp.). Before treatment, serum sIL-
2R level and IgG4-RD RI did not correlate with each other. However, the decrease in serum sIL-2R upon treatment did correlate
signiﬁcantly (P = 0 04) with the decrease in disease activity assessed by IgG-RD RI. Conclusion. Serum sIL-2R is elevated in
IgG4-RD reﬂecting the inﬂammatory process with enhanced T-cell activation. Furthermore, serum sIL-2R might serve as a
potential marker of response to treatment in IgG4-RD.
1. Introduction
IgG4-related disease (IgG4-RD) is a systemic ﬁbroinﬂam-
matory condition characterized by storiform ﬁbrotic
lesions and accumulation of IgG4-producing plasma cells
in the aﬀected tissues [1–3]. It may mimic infectious,
chronic inﬂammatory, and malignant disorders causing
delay in diagnosis [2, 3]. Yet, early diagnosis and treatment
is important to avoid irreversible organ damage due to
ﬁbrosis or secondary amyloidosis in cases of longstanding
high-inﬂammatory conditions [4, 5]. Histology remains
the gold standard in the diagnosis of IgG4-RD [2]. Serum
IgG4 is used in the diagnosis of this disease. However, it is
not a sensitive biomarker and may be normal in histology
proven cases [2].
The pathogenesis of IgG4-RD is mostly unclear, but B
cells, IgG4-positive plasma cells, and IgG4 antibodies as well
as the oligoclonal expansion of T-cells seem to play an
important role in the immunopathophysiology [6–9]. T fol-
licular helper-2 (Tfh2) cells are involved in driving the class
switch to IgG4 [10]. Cytokines, including interleukin- (IL-)
4 and transforming growth factor β, derived from T-helper
2 (Th2) cells and regulatory T-cells, may also contribute to
the pathophysiology of IgG4-RD [9, 11–13]. However, the
exact role of Th2 cells and their speciﬁc cytokines in IgG4-
RD is still a subject of debate [14, 15]. Also, CD4+ T-cells that
display cytotoxic features are abundant in the peripheral
blood and diseased tissue sites of IgG4-RD patients and
may contribute to the chronic inﬂammatory/ﬁbrotic network
via secretion of speciﬁc cytokines [8, 16].
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Peripheral blood levels of soluble IL-2 receptor (sIL-
2R) reﬂect the level of T-cell activation. Elevated serum
levels of sIL-2R correlate with disease activity in rheuma-
toid arthritis and sarcoidosis, diseases in which enhanced
T-cell activity is centrally involved [17–20]. Moreover,
increasing serum sIL-2R levels may precede T-cell-driven
ﬁbrotic responses [21]. In light of the above and as
suggested previously [22], serum sIL-2R may also be ele-
vated in IgG4-RD and represent a maker for monitoring
disease activity.
Here we examined sIL-2R serum levels in a cohort of
histologically diagnosed and therapy-naïve patients with
IgG4-RD in comparison to patients with untreated sarcoido-
sis and controls (blood bank donors). Moreover, serum sIL-
2R levels were related to clinical response upon treatment.
2. Methods
2.1. Study Population. The Erasmus MC University Medical
Center represents a national referral center for patients with
IgG4-RD. Medical records of patients with IgG4-RD between
1999 and July 2017 were reviewed for clinical characteristics
and the availability of serum sIL-2R measurements. Only
patients with histologically conﬁrmed IgG4-RD according
to established Boston criteria for histology [23], and of whom
serum sIL-2R levels were available, were included. In total,
serum sIL-2R levels were available from 26 patients with
clinically active IgG4-RD. The serum sIL-2R levels from
these patients were compared to those of patients with histo-
logically proven sarcoidosis (n = 78, from the Erasmus MC
University Medical Center sarcoidosis database) and controls
Table 1: Characteristics of patients with IgG4-RD.
P Sex Age
Disease manifestation
of IgG4-RD
IgG4 before
treatment
sIL-2R before
treatment
Treatment/comments
1 M 53 Orbit and lymph nodes 17.7 3695 Rx: prednisone
2 M 36 Salivary gland 3.18 3441 Rx: initially prednisone and Aza, later RTX
3 M 42 Lymph nodes and kidney 3.0 12,400 Rx: prednisone and RTX, now CellCept
4 M 60 Orbit and lymph nodes 5.22 3700 Rx: prednisone and MTX
5 F 46 Orbit 2.76 3400 Rx: now inﬂiximab
6 M 61 Orbit, lymph node, and prostate 13.48 5800
sIL-2R initially measured under low-dose prednisone
but active disease. Now prednisone and MTX
7 M 57
Orbit, lymph node, and prostate
and pancreas
13.40 5151 Rx: prednisone
8 M 63
Orbit, pancreas, ENT, and
prostate
1.65 5700 Rx: prednisone
9 M 17 Lung, lymph nodes, and brain 10.30 3900 Rx: prednisone and RTX
10 M 53 Mesenteric manifestation 25.25 5900 Rx: prednisone and RTX
11 M 32
Pericardial and pleural
manifestation
5.40 3500 Rx: prednisone
12 M 39 Orbit 1.65 8135 Rx: prednisone and Aza
13 M 29 Lymph node (Kimura disease) 1.17 3800 Patient declined treatment
14 M 55 Hypophysis and ENT 1.57 3100 Rx: prednisone
15 M 48 Mesenteric manifestation 3.01 14,027 Patient did not show up for follow-up/treatment
16 F 52 Orbit 0.61 2859
Surgical resection periorbital mass, no systemic
treatment
17 M 61 Biliary tract and ENT 5.55 5300 Rx: prednisone
18 M 79 Lymph node 42.8 9000
Only lymph node manifestation, no systemic
treatment
19 F 39 Salivary gland 3.97 3374 Rx: prednisone
20 M 74 Orbit and lymph node 8.82 6135 Rx: dexamethasone
21 F 52 Orbit and lymph node 3.27 2639 Rx: prednisone
22 M 74 Orbit and ENT 3.30 7977
Status after ocular surgery, currently no systemic
treatment
23 F 61 Orbit and ENT 0.36 4182 Rx: prednisone
24 M 65 Retroperitoneal ﬁbrosis 3.44 7100 Rx: prednisone
25 M 53 Orbit and ENT 1.45 4105 Rx: prednisone, MTX, and now RTX
26 F 59 Skin 1.18 10,800 Rx: prednisone and Plaquenil
Characteristics of patients with IgG4-RD, including serum IgG4 and serum sIL-2R before treatment. P = patient; Rx = treatment; MTX=methotrexate;
Aza = azathioprine; RTX = rituximab, NA = not applicable; NM= not measured. Normal range of serum IgG4 is 0.08–1.40 g/l, and normal range of serum
sIL-2R is below 2500 pg/ml.
2 Mediators of Inﬂammation
(n = 101, anonymous blood bank donors). Serum sIL-2R
levels in untreated IgG4-RD patients were compared to
serum sIL-2R levels after starting treatment (available in 15
patients). The disease activity at the time of measurement
of serum sIL-2R levels before and after starting treatment
was assessed using the IgG4-RD Responder Index (IgG4-
RD RI) [24]. This study was performed according to the Dec-
laration of Helsinki and was approved by the Medical Ethics
Committee of Erasmus MC (ethics approval numbers MEC-
2014-476, MEC-2015-200, and MEC-2017-084).
2.2. Analysis of Serum Parameters. Serum IgG4 and sIL-2R
levels were measured by the standard laboratory diagnostic
facility within Erasmus MC. IgG4 was measured by immuno-
nephelometry using a Siemens BN II nephelometer, and
serum sIL-2R levels were determined with ELISA (Diaclone,
Besancon Cedex, France) according to manufacturer instruc-
tions in pg/ml. The reference range of sIL-2R is set
at <2500 pg/ml within Erasmus MC, based on the serum
sIL-2R measurements in 101 blood bank donors. C-
reactive protein (CRP) was determined from plasma on a
Roche Cobas 8000 analyzer using an immunoturbidimetric
assay (Roche Diagnostics). In short, human CRP aggluti-
nates with latex particles coated with monoclonal anti-CRP
antibodies. The aggregates are determined turbidimetrically.
2.3. Statistical Analysis. Characteristics of the patients with
IgG4-RD and sarcoidosis and the controls were described
using descriptive statistics. We tested for diﬀerences between
the three groups of IgG4-RD, sarcoidosis, and controls using
a one-way ANOVA. To investigate the individual diﬀerences
between the groups (IgG4-RD versus controls, sarcoidosis
versus controls, and IgG4R versus sarcoidosis), we used inde-
pendent sample t-tests. Because we used multiple t-tests, this
could be classiﬁed as multiple testing. Therefore, we used a
stricter P value for those 3 speciﬁc tests (P < 0 01 is consid-
ered signiﬁcant). For all other statistical tests performed, we
used the standard P value (P < 0 05 is considered signiﬁcant).
To investigate whether serum sIL-2R levels changed after
treatment, a dependent sample t-test was performed. When
calculating correlations, we used the Spearman’s rank cor-
relation coeﬃcient. The statistical analyses were performed
using IBM SPSS statistics 21.0.0 for Windows (SPSS Inc.,
Chicago, IL, USA).
3. Results
3.1. Patient Characteristics. Table 1 demonstrates the charac-
teristics of patients with IgG4-RD. Patients with IgG4-RD
represent a heterogeneous group, and 58% of the patients
presented with involvement of more than one organ.
Table 2 shows the descriptive characteristics of patients with
IgG4-RD and sarcoidosis and controls and the serum levels
of sIL-2R. There was no diﬀerence between the mean age of
IgG4-RD patients and sarcoidosis patients (P = 0 311). Sig-
niﬁcantly more patients with IgG4-RD were male (76.9%).
The blood bank donors were anonymous. Therefore, no data
was present on the age or sex of these volunteers.
3.2. sIL-2R Levels in the Study Population. The median level
of serum sIL-2R in IgG4-RD was 4667 pg/ml; in sarcoidosis,
6050 pg/ml; and in the control population, 1515 pg/ml.
Serum sIL-2R levels in IgG4-RD were signiﬁcantly higher
compared to those in controls (P < 0 001) and lower com-
pared to those in sarcoidosis (P = 0 004) (Table 2, Figure 1).
3.3. sIL-2R Levels after Treatment in IgG4-RD. Serum sIL-2R
levels of 15 IgG4-RD patients were also available after treat-
ment and decreased signiﬁcantly from 5300 pg/ml (3695–
6135) to 2864pg/ml (2160–3653) (P = 0 001). The duration
of treatment varied per patient, but all patients of whom
serum sIL-2R levels were available after treatment showed
signiﬁcant clinical improvement on IgG-RD RI in response
to treatment (P = 0 01, Table 3).
3.4. The Correlation of Serum sIL-2R with Serum IgG4, CRP,
and IgG-RD Responder Index. In 19 patients with IgG4-RD,
Table 2: The descriptive characteristics of the study population.
IgG4-RD patients Sarcoidosis patients Controls (anonymous blood bank donors)
Number 26 78 101
Median age (IQR) 53 years (41–61) 49 years (38–56) Not applicable
Males 20 (76.9%) 37 (47.7%) Not applicable
Females 6 (23.1%) 41 (52.6%) Not applicable
Median serum sIL-2R (IQR) 4667 pg/ml (3485–7319) 6050 pg/ml (4651–9475) 1515 pg/ml (1150–1880)
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Figure 1: Boxplot of serum sIL-2R levels. Boxplots of serum sIL-2R
(pg/ml) in newly untreated sarcoidosis and IgG4-RD and sIL-2R
levels after initiation of treatment in IgG4-RD and in control
population. ∗P = 0 004; ∗∗P < 0 001; ∗∗∗P = 0 001.
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serum IgG4 levels were available before and after treatment
and decreased signiﬁcantly (P = 0 001) from 4.0 g/l (1.7–
10.3) to 1.8 g/l (1.3–3.3) and correlated with a clinical
improvement of the disease. In all IgG4-RD patients,
serum sIL-2R was elevated, compared to 85% (22/26) for
serum IgG4 (Table 1). No signiﬁcant correlation was
observed between the levels of serum sIL-2R and serum
IgG4 before (Spearman’s rho: −0.08, P = 0 776) and after
(Spearman’s rho: 0.225, P = 0 450) treatment. Elevated CRP
levels (CRP ≥ 10mg/l) were found in 27% (7/26) of patients
before treatment. No signiﬁcant correlation was observed
between the levels of CRP and serum sIL-2R before (Spear-
man’s rho: 0.299, P = 0 279) and after (Spearman’s rho:
0.379 P = 0 164) treatment. Serum sIL-2R and IgG4-RD RI
did not correlate with each other before treatment (Spear-
man’s rho: −0.119, P = 0 672). However, the decrease in
serum sIL-2R signiﬁcantly correlated with the decrease in
disease activity assessed by IgG-RD RI (Figure 2, Spearman’s
rho: 0.527, P = 0 044).
4. Discussion
Here we demonstrate that serum sIL-2R levels are elevated in
all patients with active and untreated IgG4-RD. Furthermore,
the decrease in sIL-2R levels after treatment signiﬁcantly
correlates with clinical improvement in a small cohort of
patients with IgG4-RD.
It has been described that sIL-2R levels may diﬀer with
age, with children (age 1–14 years) and elderly (age 67–99
years) having higher sIL-2R levels as compared to (young)
adults (age 22–67) [20, 25]. We used anonymous blood
donors as the control in our study. In the Netherlands, blood
donors will be mostly within this (young) adult age group, as
were most of the IgG4-RD patients (and sarcoidosis patients)
included in our study. Therefore, we consider it unlikely that
age diﬀerences between groups inﬂuenced the outcome of
our study. This is further supported by previous studies that
described elevated sIL-2R levels in IgG4-RD, especially in
relation to the higher percentage (>40%) of IgG4-positive
plasma cells in the salivary gland tissues [22], glycolysis
within the tissues [26], and increased levels of CC-
chemokine ligand 18 (CCL18), a substantial marker for
ﬁbrotic diseases [27].
Our observations in patients with clinically active IgG4-
RD suggest that serum sIL-2R reﬂects the inﬂammatory pro-
cess in these patients. sIL-2R is secreted by activated T-cells,
and elevated levels are used as marker for T-cell activity in
other inﬂammatory diseases [28]. Although the pathophysio-
logical mechanism of IgG4-RD is not yet fully elucidated, T-
cell activation is currently considered an important contribu-
tor [6, 8, 9]. The levels of serum sIL-2R and the disease activ-
ity score (IgG4-RD RI) before treatment did not show a
signiﬁcant correlation, but our observation of declining sIL-
2R serum levels upon clinical improvement after immuno-
suppressive treatment supports the pathological role of
(excessive) T-cell activity in IgG4-RD and further indicates
that serum sIL-2R levels reﬂect IgG4-RD disease activity.
Although the posttreatment measurement intervals of serum
sIL-2R diﬀered in patients, it will probably not have inﬂu-
enced the results, because the decrease in sIL-2R correlated
with clinical improvement of the disease activity obtained
by IgG4-RD RI.
Theoretically, serum IgG4 levels might reﬂect disease
activity in IgG4-RD. However, in general, serum IgG4 is nor-
mal in ~30% of IgG4-RD patients [1]. Indeed 15% of our
patients with IgG4-RD had normal serum IgG4 levels, whilst
serum sIL-2R was elevated in all patients. Moreover, there
was no direct correlation between serum IgG4 and sIL-2R
Table 3: Treatment response in IgG4-RD.
P
IgG4 before
treatment
IgG4 after
treatment
sIL-2R before
treatment
sIL-2R after
treatment
CRP before
treatment
CRP after
treatment
IgG4-RD RI before
treatment
IgG4-RD RI after
treatment
1 17.7 10.10 3695 3443 1.8 1.6 9 3
2 3.18 3.32 3441 2864 1.0 2.5 4 2
4 5.44 0.46 3700 1600 0.5 0.9 6 1
6 13.48 6.70 5800 2900 0.3 0.3 10 4
7 13.40 3.27 5151 3653 4.7 1.4 10 3
8 1.65 0.28 5700 2800 1.0 0.6 6 1
9 10.30 4.99 3900 1800 50.0 4.5 7 3
10 25.25 4.58 5900 4300 80.0 35.0 6 2
11 5.40 2.79 3500 819 4.8 0.4 5 1
12 1.65 1.54 8135 3700 10.0 7.5 6 1
14 1.57 1.33 3100 2160 5.2 10.0 6 3
17 5.55 1.84 5300 2200 0.3 0.3 6 1
20 8.82 1.28 6135 2222 2.8 38 4 0
24 3.44 1.35 7100 3616 31 6.8 6 1
26 1.29 1.76 10,800 5000 8.0 7.6 4 3
Treatment response in IgG4-RDwith levels of serum IgG4, CRP, and sIL-2R before and after treatment. The disease activity has been measured using the IgG4-
RD RI. Normal range of serum IgG4 is 0.08–1.40 g/l, normal range of serum sIL-2R is below 2500 pg/ml, and normal range of CRP is below 10mg/l.
CRP = C-reactive protein; IgG4-RD RI = IgG4-Related Disease Responder Index.
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and between CRP and serum sIL-2R levels in the cohort
studied.
Sarcoidosis often presents with clinical presentations
similar to IgG4-RD and is associated with elevated serum
sIL-2R (this study and others), and if untreated, ﬁbrosis
may develop [17, 18, 29]. Consequently, sarcoidosis repre-
sents an appropriate disease control for comparison of serum
sIL-2R levels with IgG4-RD. The serum levels of sIL-2R were
signiﬁcantly lower in IgG4-RD compared to sarcoidosis, yet
signiﬁcantly higher than that observed in the control popula-
tion. This may be indicative of a more vigorous T-cell com-
ponent, or burden of activated T-cells, in sarcoidosis.
Because sIL-2R is a non-disease-speciﬁc T-cell activation
marker, it might not suite as a speciﬁc diagnostic tool in
IgG4-RD [19]. However, as all IgG4-RD patients displayed
elevated serum sIL-2R, compared to 85% and 27% for serum
IgG4 and CRP, respectively, its negative predictive value can
be considered high and thus may be helpful in diagnostic
evaluation of IgG4-RD. Moreover, sIL-2R could be useful in
monitoring disease activity, disease dynamics, and early
detection of a recurrence.
This study is limited by its retrospective character and the
relatively small population. Therefore, larger studies are
required to obtain the sensitivity and speciﬁcity of sIL-2R
in IgG4-RD.
In conclusion, we demonstrate that serum sIL-2R is
elevated in IgG4-RD. Furthermore, serum sIL-2R may
have potential as a tool for monitoring disease activity/
treatment response in IgG4-RD. The value of serum sIL-
2R for this application needs further conﬁrmation in pro-
spective and larger studies, also in comparison to diseases
with the capacity to mimic IgG4-RD such as granulomato-
sis with polyangiitis.
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